Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,180.42 -7.28 (-0.14%) Dow
38,952.67 +68.41 (+0.18%) Nasdaq
16,280.36 -52.19 (-0.32%) Bitcoin USD
62,353.06 -1,185.61 (-1.87%) CMC Crypto 200
1,323.54 +28.86 (+2.23%)
ESPR Jan 2025 10.000 put
| Previous close | 8.00 |
| Open | 8.00 |
| Bid | 7.90 |
| Ask | 8.40 |
| Strike | 10.00 |
| Expiry date | 2025-01-17 |
| Day's range | 8.00 - 8.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 19 |
Insider MonkeyEsperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript May 7, 2024 Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.00032, expectations were $-0.17. ESPR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for […]
- GuruFocus.com
Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...
Discover how Esperion Therapeutics achieved a historic revenue milestone and expanded market potential in its first quarter of 2024.
BenzingaHeart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05. U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growt
